Wednesday, February 19, 2025 Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre,open-label,multiarm, biomarker-directed,signal-seeking,umbrella,clinical trial for recurrent IDH mutant,grade 2/3 gliomaMcParland K, Koh E-S, Kong B, Sim H-W, Thavaneswaran S, Yip S, Barnes EH, Ballinger ML, Thomas DM, De Abreu Lourenco R, Simes J, Sebastian L, Wheeler PJ, Spyridopoulos D, Hawkins C, Pitz M, O'Callaghan C, Gan HK. Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma. BMJ Open 15: e087922. 2025.https://bmjopen.bmj.com/content/bmjopen/15/2/e087922.full.pdf This study aimed to improve outcomes by molecular profiling of patients at relapse, then matching them with the best available drug based on their molecular profile, maximising the chances of patient benefit while simultaneously testing multiple novel drugs.
